The company has not filed an annual or quarterly report since its FY2020 20-F, filed Mar 30, 2021. Its latest SEC filing is a SC 13D/A from Mar 8, 2022.
20-F for FY2020, filed Mar 30, 2021
The sections below describe the company as of the FY2020 annual report.
Develops lipid-based medicines using approved drug ingredients for pain, eye conditions and cancer. Licenses drug-product rights to pharmaceutical companies.
20-F for FY2020, filed Mar 30, 2021
Pharmaceutical companies are customers under drug-rights and development agreements, through which the company continues research and development on the products.
20-F for FY2020, filed Mar 30, 2021The Group’s authorization collaboration and development transactions generally authorizes intellectual property rights of the drug products…View ↗
Competes with Flexion Therapeutics, Pacira Pharmaceuticals, Heron Therapeutics, and Allergan
20-F for FY2020, filed Mar 30, 2021We are initially developing TLC599 for OA pain. Current approved intraarticular treatments of OA pain include steroids and hyaluronic acid…View ↗
Loading...
